June 4, 2019 Cell Analysis Tools PR/Corporate

Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer

SOUTH SAN FRANCISCO, Calif., June 04, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that Andrew Quong, PhD, has joined the company as its first-ever Chief Science Officer.  Quong will lead the company’s strategy for the generation of bold scientific insights in immunology, immuno-oncology and other frontiers of human health based on Fluidigm® technology. He will develop and integrate Fluidigm’s science... Read more

May 29, 2019 Life Science Tools Product Launch

Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology

The first commercially available targeted NGS assay that enables simultaneous detection of somatic variants across 53 solid tumor genes using a highly efficient microfluidic library prep workflow SOUTH SAN FRANCISCO, Calif., May 29, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today introduced the Advanta™... Read more

March 28, 2019 Clinical Research/Diagn. Mass Spectrometry Product Launch

Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry

The new standard in immune profiling for advancing translational and clinical research of immune-mediated diseases SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the Maxpar® Direct™ Immune Profiling System. Setting the new standard in immune... Read more

March 5, 2019 PR/Corporate

Colin McCracken Joins Fluidigm as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and existing markets and expanding the company’s global reach. As a member of the executive leadership team reporting to President... Read more

February 7, 2019 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships Mass Spectrometry

Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM) today announced it is one of 11 partners in the TIMID Consortium, a unique effort of six academic institutions and five life science and pharma companies that utilizes both mass cytometry and Imaging Mass Cytometry™ along with other technologies to explore the common cellular basis of... Read more

February 7, 2019 Clinical Research/Diagn. M&A, Partnerships

Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of the agreement, Fluidigm and Indica Labs will cooperatively promote the next-generation digital pathology image analysis and image management platforms HALO®, HALO AI™and HALO Link™ in conjunction with... Read more

January 31, 2019 Life Science Tools Product Launch

Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of a REAP-seq (RNA expression and protein sequencing) protocol for use with the C1™ system. C1 REAP-seq is a powerful multi-omic single-cell application that enables deep characterization of unique cellular subtypes and functional states... Read more

December 14, 2018 Cell Analysis Tools PR/Corporate

Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares

PDF Version SOUTH SAN FRANCISCO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock. The stock was sold at a price to the public of $6.75 per share, for aggregate gross proceeds of... Read more

December 11, 2018 Cell Analysis Tools PR/Corporate

Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock

PDF Version SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75 per share for aggregate gross proceeds of approximately $55 million. Fluidigm has granted to the underwriters... Read more

December 11, 2018 Cell Analysis Tools PR/Corporate

Fluidigm Announces Commencement of Public Offering of Common Stock

PDF Version SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering pursuant to Fluidigm’s existing shelf registration statement. In connection with... Read more